Literature DB >> 27730299

Peripheral VH4+ plasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients.

Jacqueline R Rivas1, Sara J Ireland1, Rati Chkheidze2, William H Rounds1, Joseph Lim1, Jordan Johnson1, Denise M O Ramirez1, Ann J Ligocki1, Ding Chen1, Alyssa A Guzman1, Mark Woodhall3, Patrick C Wilson4, Eric Meffre5, Charles White2, Benjamin M Greenberg1, Patrick Waters3, Lindsay G Cowell6, Ann M Stowe1, Nancy L Monson7,8.   

Abstract

Plasmablasts are a highly differentiated, antibody secreting B cell subset whose prevalence correlates with disease activity in Multiple Sclerosis (MS). For most patients experiencing partial transverse myelitis (PTM), plasmablasts are elevated in the blood at the first clinical presentation of disease (known as a clinically isolated syndrome or CIS). In this study we found that many of these peripheral plasmablasts are autoreactive and recognize primarily gray matter targets in brain tissue. These plasmablasts express antibodies that over-utilize immunoglobulin heavy chain V-region subgroup 4 (VH4) genes, and the highly mutated VH4+ plasmablast antibodies recognize intracellular antigens of neurons and astrocytes. Most of the autoreactive, highly mutated VH4+ plasmablast antibodies recognize only a portion of cortical neurons, indicating that the response may be specific to neuronal subgroups or layers. Furthermore, CIS-PTM patients with this plasmablast response also exhibit modest reactivity toward neuroantigens in the plasma IgG antibody pool. Taken together, these data indicate that expanded VH4+ peripheral plasmablasts in early MS patients recognize brain gray matter antigens. Peripheral plasmablasts may be participating in the autoimmune response associated with MS, and provide an interesting avenue for investigating the expansion of autoreactive B cells at the time of the first documented clinical event.

Entities:  

Keywords:  Antigen receptor genetics; Autoantibody; B cell; Multiple sclerosis; Plasmablast

Mesh:

Substances:

Year:  2016        PMID: 27730299      PMCID: PMC5312707          DOI: 10.1007/s00401-016-1627-0

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  107 in total

Review 1.  The generation of antibody diversity through somatic hypermutation and class switch recombination.

Authors:  Ziqiang Li; Caroline J Woo; Maria D Iglesias-Ussel; Diana Ronai; Matthew D Scharff
Journal:  Genes Dev       Date:  2004-01-01       Impact factor: 11.361

2.  Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid.

Authors:  Gregory P Owens; Alanna M Ritchie; Mark P Burgoon; R Anthony Williamson; John R Corboy; Donald H Gilden
Journal:  J Immunol       Date:  2003-09-01       Impact factor: 5.422

3.  Phenotypic characterization of autoreactive T cells in multiple sclerosis.

Authors:  Robert B Ratts; Nitin J Karandikar; Rehana Z Hussain; Judy Choy; Sara C Northrop; Amy E Lovett-Racke; Michael K Racke
Journal:  J Neuroimmunol       Date:  2006-08-08       Impact factor: 3.478

4.  Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation.

Authors:  Eduardo Beltrán; Birgit Obermeier; Markus Moser; Francisco Coret; María Simó-Castelló; Isabel Boscá; Francisco Pérez-Miralles; Luisa M Villar; Makbule Senel; Hayrettin Tumani; Reinhard Hohlfeld; Bonaventura Casanova; Klaus Dornmair
Journal:  Brain       Date:  2014-07-23       Impact factor: 13.501

Review 5.  B cell antigen receptor signaling: roles in cell development and disease.

Authors:  Stephen B Gauld; Joseph M Dal Porto; John C Cambier
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

6.  Clonally expanded plasma cells in the cerebrospinal fluid of patients with central nervous system autoimmune demyelination produce "oligoclonal bands".

Authors:  Hans-Christian von Büdingen; Monica Gulati; Sandra Kuenzle; Katja Fischer; Tobias A Rupprecht; Norbert Goebels
Journal:  J Neuroimmunol       Date:  2009-11-08       Impact factor: 3.478

7.  Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis.

Authors:  Elizabeth M Cameron; Sade Spencer; Jonathan Lazarini; Christopher T Harp; E Sally Ward; Mark Burgoon; Gregory P Owens; Michael K Racke; Jeffrey L Bennett; Elliot M Frohman; Nancy L Monson
Journal:  J Neuroimmunol       Date:  2009-07-24       Impact factor: 3.478

Review 8.  B-cell antigen-receptor signalling in lymphocyte development.

Authors:  Leo D Wang; Marcus R Clark
Journal:  Immunology       Date:  2003-12       Impact factor: 7.397

9.  Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response.

Authors:  Diana G Adlowitz; Jennifer Barnard; Jamie N Biear; Christopher Cistrone; Teresa Owen; Wensheng Wang; Arumugam Palanichamy; Ezinma Ezealah; Debbie Campbell; Chungwen Wei; R John Looney; Inaki Sanz; Jennifer H Anolik
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

10.  Oligodendrocyte-specific expression and autoantigenicity of transaldolase in multiple sclerosis.

Authors:  K Banki; E Colombo; F Sia; D Halladay; D H Mattson; A H Tatum; P T Massa; P E Phillips; A Perl
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

View more
  14 in total

Review 1.  Pathogenic autoantibodies in multiple sclerosis - from a simple idea to a complex concept.

Authors:  Romana Höftberger; Hans Lassmann; Thomas Berger; Markus Reindl
Journal:  Nat Rev Neurol       Date:  2022-08-15       Impact factor: 44.711

2.  Clonal expansion and markers of directed mutation of IGHV4-34 B cells in plasmablasts during Kawasaki disease.

Authors:  Arthur J Chang; Sarah Baron; Jonathon Hoffman; Mark D Hicar
Journal:  Mol Immunol       Date:  2022-03-15       Impact factor: 4.174

3.  Suppressed plasmablast responses in febrile infants, including children with Kawasaki disease.

Authors:  Meghan Martin; Brian H Wrotniak; Mark Hicar
Journal:  PLoS One       Date:  2018-03-26       Impact factor: 3.240

Review 4.  [Ocrelizumab for treatment of multiple sclerosis].

Authors:  Jonas Graf; Philipp Albrecht; Norbert Goebels; Orhan Aktas; Hans-Peter Hartung
Journal:  Nervenarzt       Date:  2020-06-10       Impact factor: 1.214

5.  Immunophenotype and Transcriptome Profile of Patients With Multiple Sclerosis Treated With Fingolimod: Setting Up a Model for Prediction of Response in a 2-Year Translational Study.

Authors:  Irene Moreno-Torres; Coral González-García; Marco Marconi; Aranzazu García-Grande; Luis Rodríguez-Esparragoza; Víctor Elvira; Elvira Ramil; Lucía Campos-Ruíz; Ruth García-Hernández; Fátima Al-Shahrour; Coral Fustero-Torre; Alicia Sánchez-Sanz; Antonio García-Merino; Antonio José Sánchez López
Journal:  Front Immunol       Date:  2018-07-25       Impact factor: 7.561

Review 6.  Single-Cell High-Throughput Technologies in Cerebrospinal Fluid Research and Diagnostics.

Authors:  Tobias V Lanz; Anne-Katrin Pröbstel; Iris Mildenberger; Michael Platten; Lucas Schirmer
Journal:  Front Immunol       Date:  2019-06-11       Impact factor: 7.561

7.  Anti-Myelin Proteolipid Protein Peptide Monoclonal Antibodies Recognize Cell Surface Proteins on Developing Neurons and Inhibit Their Differentiation.

Authors:  Raymond A Sobel; Mary Jane Eaton; Prajakta Dilip Jaju; Eugene Lowry; Julian R Hinojoza
Journal:  J Neuropathol Exp Neurol       Date:  2019-09-01       Impact factor: 3.685

Review 8.  B cells in autoimmune and neurodegenerative central nervous system diseases.

Authors:  Joseph J Sabatino; Anne-Katrin Pröbstel; Scott S Zamvil
Journal:  Nat Rev Neurosci       Date:  2019-11-11       Impact factor: 34.870

9.  Molecular Level Characterization of Circulating Aquaporin-4 Antibodies in Neuromyelitis Optica Spectrum Disorder.

Authors:  Jie Li; Sam A Bazzi; Florian Schmitz; Hidetaka Tanno; Jonathan R McDaniel; Chang-Han Lee; Chaitanya Joshi; Jin Eyun Kim; Nancy Monson; Benjamin M Greenberg; Kristina Hedfalk; Esther Melamed; Gregory C Ippolito
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-06-24

10.  Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination.

Authors:  Patrick Peschl; Kathrin Schanda; Bleranda Zeka; Katherine Given; Denise Böhm; Klemens Ruprecht; Albert Saiz; Andreas Lutterotti; Kevin Rostásy; Romana Höftberger; Thomas Berger; Wendy Macklin; Hans Lassmann; Monika Bradl; Jeffrey L Bennett; Markus Reindl
Journal:  J Neuroinflammation       Date:  2017-10-25       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.